<DOC>
	<DOCNO>NCT01014585</DOCNO>
	<brief_summary>The purpose study evaluate durability effect milnacipran treatment fibromyalgia patient receive long-term milnacipran treatment characterize effect milnacipran multiple symptom fibromyalgia , demonstrate change symptom follow discontinuation milnacipran .</brief_summary>
	<brief_title>Discontinuation Study Durability Effect Milnacipran Treatment Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Currently participate Study MLNMD06 Receiving stable dosage milnacipran ( 50200 mg/d ) Screening/Enrollment ( Visit 1 ) Significant risk suicide History mania , bipolar disorder , psychotic disorder , schizophrenia , current episode major depressive disorder Myocardial infarction and/or stroke within prior 12 month Mean systolic blood pressure &gt; 180 mm Hg mean diastolic blood pressure &gt; 110 mm Hg Screening ( Visit 1 ) Active liver disease Severe renal impairment Platelet bleeding disorder Female patient pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Milnacipran</keyword>
	<keyword>Pain</keyword>
	<keyword>Durability Effect</keyword>
	<keyword>Loss Therapeutic Response</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Forest Research Institute</keyword>
	<keyword>Savella Â®</keyword>
</DOC>